NCT07261774Completed
The Impact of Extreme Heat Waves and Air Pollution on the Prognosis of Chronic Airway Diseases
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Extreme heat waves (EHW) and air pollution exacerbate chronic airway diseases, but little is known about how these environmental stressors affect quality of life, airway inflammation, symptom control, and pulmonary function. This study was designed to determine the impact of EHW and air pollution on asthma and COPD. This was a prospective cohort study conducted among individuals with asthma and COPD in Mersin, Türkiye, between February 14 and December 1, 2024. Meteorological and air quality index (AQI) data were obtained from official sources. Participants underwent pulmonary function tests (PFTs) and fractional exhaled nitric oxide (FeNO) measurements during periods of normal weather conditions and repeated assessments during documented EHW periods. Patient-reported outcomes included the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ) for asthma, and the Modified Medical Research Council (mMRC) scale and COPD Assessment Test (CAT) for COPD. Exacerbation episodes requiring systemic corticosteroid use or hospitalization were also recorded. The study aimed to evaluate the effects of EHW and air pollution on disease control, quality of life, lung function, airway inflammation, and exacerbation burden in patients with asthma and COPD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 96 (actual)
- First submitted
- 29 Aug 2025
- Start date
- 6 Mar 2024
- Primary completion date
- 7 Nov 2024
- Lead sponsor
- Mersin University
- NCT number
- NCT07261774
What you commit to
- Study type: Observational
- Participants enrolled: 96
- From 6 Mar 2024 to the primary completion date, 7 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous lung surgery
Other illness
- Presence of other pulmonary diseases apart from asthma or COPD (e.g., interstitial lung diseases, pleural diseases, pulmonary vascular diseases)
- History of cancer within the past 5 years
- Active pulmonary tuberculosis
- Respiratory tract infection within the last 4 weeks
- Presence of significant extrapulmonary disease that may affect lung function (e.g., cerebrovascular disease, acute myocardial infarction)
Other
- Pregnant women
- Active smoking within the past year
- Residence outside the central district of Mersin
Who the study is looking for
- Age ≥ 18 years
- Provision of written informed consent
- For the asthma group:
- \- Diagnosis of asthma for at least 6 months according to the GINA 2024 guidelines
- Variable respiratory symptoms together with documented variable expiratory airflow limitation, demonstrated by at least one of the following:
- Positive bronchodilator reversibility test (\>12% and \>200 mL increase in FEV1 10-15 minutes after 400 μg salbutamol)
- Peak expiratory flow (PEF) variability (\>10% average daily PEF variability over 2 weeks)
- Positive delayed reversibility (improvement in lung function after 4 weeks of anti-inflammatory treatment with \>12% and \>200 mL increase in FEV1 or \>20% increase in PEF)
- Positive bronchial provocation test (≥20% fall in FEV1 with standard doses of methacholine or histamine)
- Stable disease for at least 4 weeks prior to enrollment
- For the COPD group:
- Diagnosis of COPD for at least 6 months according to the GOLD 2024 guidelines (post-bronchodilator FEV1/FVC \<70% in the presence of compatible clinical findings)
- Stable disease for at least 4 weeks prior to enrollment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mersin University Faculty of Medicin Coordinator of this site? Confirm its status | Mersin | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.